Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; and KIWI, a cloud-based Web application, which organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program. Further, the company provides consulting services ranging from early drug discovery through preclinical and clinical trial data analysis, and for submissions to regulatory agencies; and population modeling and simulation contract research services for the pharmaceutical and biotechnology industries. Additionally, it offers pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, and food companies. The company distributes its products and services worldwide. Simulations Plus, Inc. was founded in 1996 and is headquartered in Lancaster, California.
http://www.priceseries.com/trade/SLP-Simulations-Plus-Inc-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2019071020190802.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments